Journal
CHEMICAL & PHARMACEUTICAL BULLETIN
Volume 62, Issue 1, Pages 16-24Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/cpb.c13-00003
Keywords
antifungal agent; azole; Candida spp.; lanosterol 14-alpha-demethylase (CYP51) inhibitor; tetrahydroindol-4-one
Funding
- FAI-UASLP [C10-FAI-05-16.43, C10-FAI-05-14.41]
- CONACYT [217383]
Ask authors/readers for more resources
The development of antifungal drugs that inhibit lanosterol 14-alpha-demethylase (CYP51) via non-covalent ligand interactions is a strategy that is gaining importance. A series of novel tetraindol-4-one derivatives with 1- and 2-(2,4-substituted phenyl) side chains were designed and synthesized based on the structure of CYP51 and fluconazole. The antifungal activities of these derivatives against eight human pathogenic filamentous fungi and yeast strains were evaluated in vitro by measuring the minimal inhibitory concentrations. Nearly all tested compounds 8a-g displayed activity against Candida tropicalis, Candida guilliermondii and Candida parapsilosis with a minimum inhibitory concentration (MIC) value until 8 mu g mL(-1), on the other hand compounds 7a-g showed activity against Aspergillus fumigatus with a MIC value of 31.25 mu g mL(-1). A molecular modeling study of the binding interactions between compounds 6, 7d, 8g and the active site of MtCYP51 was conducted based on the computational docking results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available